Cowen and Company reiterated their hold rating on shares of BioAmber Inc. (NYSE:BIOA) in a report published on Friday. The brokerage currently has a $1.00 price target on the biotechnology company’s stock.
Other research analysts also recently issued research reports about the company. HC Wainwright reissued a buy rating and issued a $12.00 price target on shares of BioAmber in a research note on Wednesday, November 8th. Zacks Investment Research raised BioAmber from a sell rating to a hold rating in a research note on Wednesday, July 26th. Finally, ValuEngine downgraded BioAmber from a sell rating to a strong sell rating in a research note on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus target price of $6.50.
BioAmber (NYSE:BIOA) opened at $0.46 on Friday. The company has a current ratio of 1.08, a quick ratio of 0.75 and a debt-to-equity ratio of 0.24. BioAmber has a 12 month low of $0.32 and a 12 month high of $6.50.
ILLEGAL ACTIVITY WARNING: “BioAmber Inc. (BIOA) Rating Reiterated by Cowen and Company” was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.chaffeybreeze.com/2017/11/14/bioamber-inc-bioa-rating-reiterated-by-cowen-and-company.html.
Institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp raised its stake in BioAmber by 336.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 54,106 shares of the biotechnology company’s stock worth $139,000 after buying an additional 41,701 shares during the period. FMR LLC raised its stake in BioAmber by 18.7% during the 1st quarter. FMR LLC now owns 1,335,000 shares of the biotechnology company’s stock worth $3,097,000 after buying an additional 210,000 shares during the period. Robecosam AG raised its stake in BioAmber by 82.9% during the 3rd quarter. Robecosam AG now owns 1,478,000 shares of the biotechnology company’s stock worth $741,000 after buying an additional 670,000 shares during the period. Vanguard Group Inc. raised its stake in BioAmber by 9.9% during the 2nd quarter. Vanguard Group Inc. now owns 303,360 shares of the biotechnology company’s stock worth $780,000 after buying an additional 27,278 shares during the period. Finally, TD Asset Management Inc. acquired a new stake in BioAmber during the 2nd quarter worth $977,000. 36.27% of the stock is currently owned by institutional investors and hedge funds.
BioAmber Company Profile
BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.
Receive News & Ratings for BioAmber Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAmber Inc. and related companies with MarketBeat.com's FREE daily email newsletter.